Breakthrough Technology: The NeuroCuple® device leverages nano-capacitor technology to intercept and redirect pain signals, reducing intensity without drugs. Clinical studies, including an NIH-funded trial at the University of Pittsburgh Medical Center, show a 34% reduction in postoperative pain and a 52% decrease in opioid refill requests for total knee replacement patients.
Critical Market Need: Over 50 million Americans suffer from chronic pain, with opioid dependency claiming approximately 100,000 lives annually. The annual cost of pain management in the US estimated between $560-$635 Billion including direct healthcare cost, lost productivity; making it is higher than the cost of treating cancer, heart disease and diabetes COMBINED NeuroCuple® offers a safe, non-invasive, and cost-effective alternative, meeting the urgent demand for opioid-sparing solutions.
Proven and Safe: FDA-registered and manufactured in ISO-compliant facilities, NeuroCuple® devices demonstrate no adverse effects. Devices are currently being sold to the consumer market through licensee agreements, and we receive royalties for each unit sold. With pending FDA Class II clearance for surgical and chronic pain applications in 2025-2026, we are poised for clinical expansion.
Scalable Growth: Targeting 1.3 million knee replacements, 1.2 million C-sections, and over 5 million wisdom teeth extractions annually in the U.S., NCAP is scaling production and pursuing Medicare reimbursement to unlock significant revenue streams. Global markets offer 1.5 times the U.S. opportunity. Applications have been filed with the FDA to address post-op back surgery, post-op wisdom teeth removal, and post-op C-section patients. Additional trials are planned to show continued growth with new products for 3-5 years.
Strong Leadership and Milestones: Led by CEO Anthony Sutera and a seasoned team, NCAP has secured NIH STTR grants, 29 patents, and partnerships with top institutions like UPMC. Ongoing trials and planned FDA clearances position us for rapid growth. Our Chief Medical Officer, Senthil Sadhasivam, MD, MBA, MPH, is known globally as a top research doctor and is one of the researchers receiving the most grant dollars from various sources including the National Institute of Health, our primary funding partner.
Investment Ask: We are seeking USD $5 million to scale production, complete FDA trials, expand clinical use, and secure insurance reimbursement. With low production costs, non-dilutive NIH funding, and a robust IP portfolio, NCAP offers a low-risk, high-return opportunity with potential breakeven in year one. We just finished filing for additional research funding with the NIH on four other areas where our technology can reduce opioid.
Timing: We expect the next phase of FDA approvals on the total knee replacement to come mid-2025. We are a C Corp to allow for a smoother transition into the growth phase of our company. We are currently raising capital to address our growth into clinical and hospital use. We are also open to strategic partnerships with some of your portfolio companies to address manufacturing and distribution to lower costs and maximize growth.
We invite you to explore how NCAP Medical aligns with your investment goals. Contact us at
[email protected] or +1 713-894-4156 to schedule a discussion or presentation.
Ready to Ask For Funding for your company?
Post a Funding Request